When spleen cells from C.B-20 tumor-rejector mice were tested for their cytotoxic potential, they did not display activity against BCL1 or BALB/c lymphoblasts (data not shown). However, their spleen cells could be sensitized against either irradiated BCL1 or BALB/c cells in a secondary in vitro culture system so that cytotoxic activity was generated against both BCLx and BALB/c target cells (Table I) . Because these effector cells could be responsible for adoptive transfer of tumor immunity against BCLI, we further investigated the activity of effector cells generated against Ig heavy chain allotypic differences.
Specificity of CTL Generated from the Sensitization of lg H Chain Congenic Mice. C.B-20
mice were inoculated with BALB/c splenocytes. 2-6 mo later, their spleen cells were removed and the cells were cultured in vitro with irradiated BALB/c splenocytes for 5 d, at which time the cultures were assayed for cytotoxic activity against LPS lymphoblasts. The data presented in Table II 
Susceptibility of BCLt Cells to C.B-20 Anti-BALB/c Effector Cells.
We previously demonstrated (3) that C.B-20 animals that had rejected a large inocula of BCL1 cells generated cytotoxic effector cells that lysed BCL1 and BALB/c target cells (Table I ).
In the following experiments, we ascertained whether effector cells produced by in vivo immunization of C.B-20 mice with BALB/c spleen cells would also generate effector cells that could recognize BCL1 target cells. The data in Table IV demonstrate that C.B-20 anti-BALB/c effector cells are able to lyse BCL1 target cells. In this experiment, the in vivo BCL1 cells were obtained from the spleen, an organ that (in tumor-bearing animals) contains ~70% tumor cells (2) . Because it is possible that BALB/c host cells rather than BCL1 cells are responsible for the lytic effect observed, we also tested an in vitro-adapted BCL1 cell line (14) . The data (Table IV) demonstrate that these in vitro-cultured cells are sensitive to lysis. Thus, the anti-Ig H region CTL do recognize antigenic determinants expressed by BCL1. BCL1 cells have been fused to the myeloma line, X63. This hybridoma secretes IgM, which bears the same idiotypic determinants expressed on the IgM and IgD of the parental BCLx tumor cell, as well as the IgGlk from the X63 cells (13) . However, when this hybridoma line was tested for its sensitivity to lysis, no cytotoxic effect was observed (Table IV) .
Specificity of C.B-20 Anti-BALB/c Effector Cells
These three BCL1 lines were also analyzed for cell surface Ig expression using the FACS. The data in Fig. 1 reveal that the two BCL1 lines contain a large percentage of sIg + cells (>50%), with a relatively heterogenous distribution of staining intensity. On the other hand, the BCLa hybridoma line contains very few sIg + cells, and these cells stain with a relatively low intensity.
Therefore, these results suggest that the expression of sIg is necessary for a target cell to be sensitive to lysis by anti-Ig H chain effector cells.
Susceptibility of Tumor Lines to Lysis by Anti-Ig H Effector Cells.
Because the BCLa (sIg +) B cell leukemia was killed by C.B-20 anti-BALB/c effector cells, we next determined whether other BALB/c tumor cells also expressed the target antigen. Target cells included IgA-, IgGa-, and IgD-secreting myeloma cells and a thymic lymphoma (P 1798).
The data indicate that none of these tumor cells were sensitive to lysis by either C.B-20 anti-BALB/c or BALB/e anti-C.B-20 effector cells (Table V) . The latter effector cells were used because three of the myelomas tested, MOPC 315, MOPC 300, and MOPC 245, are genotypically heterozygous at Ig-1; i.e., they were obtained from mice during backcrossing to generate the C.B-20 congenic line (17, 18) and could be sensitive to lysis as were (BALB/c × B6)F1 target cells (see Table II ). The data also show that although the MOPC 315, MOPC 300, and P1798 cell lines are insensitive to lysis by C.B-20 anti-BALB/c effector cells, they are all sensitive to lysis by anti-H-2 CTL (B10.Q anti-BALB/c).
If Ig is the target antigen, then it is possible that secreted Ig from myeloma cells could adsorb onto unlabeled cells in the effector cell population and block or inhibit lysis. However, this alternative is unlikely. Thus, LPS induced B lymphoblasts and (21) . Table VI summarizes experiments that include all of the tumor lines that were tested for the presence of the target antigen. The data indicate that only sIg + BCL1 cells are sensitive to lysis, whereas IgG-, IgM-, IgD-, and IgA-secreting myeloma cells, which have been reported to express low amounts of sIg (22), are negative.
Sensitivity of Splenic B and T Cell Lymphoblasts to Anti-Ig H Effector Cells.
The previous data indicate that not all tissues of BALB/c origin express detectable quantities of the antigenic determinants recognized by C.B-20 anti-BALB/c effector cells. Therefore, experiments were performed to ascertain whether splenic T and B cell lymphoblasts were equally sensitive to lysis.
The data in Table VII indicate that both splenic LPS and Con A lymphoblasts were sensitive to lysis by anti-Ig H region effector cells, although LPS blasts were usually more sensitive than Con A blasts. Because splenic Con A blasts contain a considerable portion of Ig ÷ cells and splenic LPS blasts contain a considerable portion of Ig-cells, we purified T and B cells from spleens and then cultured each with either Con A or LPS, respectively. These populations of T and B cell lymphoblasts were enriched for the appropriate cells and showed relatively little cross contamination (see footnotes to Table VI) . When these cells were tested for their sensitivity to lysis, it was noted that the LPS-stimulated B lymphoblasts were usually more sensitive to lysis than the LPS-stimulated splenic lymphoblasts, whereas the Con A-stimulated T lymphoblasts dislayed little or no sensitivity to lysis. It should also be noted that the four types of target cells tested were equally sensitive to lysis by anti-H-2 effector cells (B 10.Q anti-BALB/c).
Therefore, these data indicate that the target antigen(s) recognized by anti-Ig H region effector cells have a restricted tissue distribution that appears to be coincident with the expression of sIg. 
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Ig-l" -- Discussion The data in this report provide the first direct evidence for the existence of CTL specific for antigenic determinants expressed on sIg + cells. The target antigens recognized by these CTL are encoded for by genes either linked to or identical with Ig H chain loci. Furthermore, because C.B-20 anti-BALB/c effector cells do not lyse BAB-14 lymphoblasts, the antigen recognized on BALB/c targets is encoded for by a gene linked to the C rather than the V region of the Ig-1 locus. Thus, our data demonstrate that the target antigens detected by the cytotoxic effector cells generated in this system are expressed on LPS-induced B cell lymphoblasts but not Con Ainduced T cell lymphoblasts or a T cell leukemia. Although this indicates that the target antigens are expressed on cells of the B and not the T cell lineage, these antigens are not expressed on all cells of B cell origin. We were unable to detect target antigens on several myeloma cell lines that have been reported to have low levels of sIg (reviewed in 22). On the other hand, BCL1, an sIg + B cell leukemia was sensitive to lysis. Furthermore, a BCLa × X63 hybridoma line that secretes the same IgM as is expressed on the surface of the parental BCL1 line, but displays almost no sIg, was not lysed by the anti-Ig H effector cells. Taken together, these data suggest that the target antigen being detected by the CTL is either sIg itself or a determinant that is coordinately expressed on Ig + B cells.
These data provide a possible mechanism whereby CTL could regulate B cells expressing cell membrane allotypic (Ig) determinants. This type of activity would be consistent with previous studies indicating that other subpopulations of T lympho- Rolink et al. (11) reported that CTL could be generated using allotype congenic strains that were similar but not identical to those used in this study. The effector cells they described detected an antigen expressed on a T cell tumor as well as both T and B cell lymphoblasts. In contrast, the antigen recognized by the cytotoxic cells generated here were restricted to sIg + B cells. This discrepancy between the two sets of data could be due to the fact that the BALB/c animals used by Rolink et al. (11) may differ at an/g-linked H-antigen locus from the BALB/c line used to derive the allotype congenic strains. Accordingly, the CTL generated by Rolink et al. The activity of the CTL from these mice may be similar to that described by Rolink et al. (11) and is also consistent with the data of Riblet et al. (31) , who demonstrated that allotype congenic strains reject skin grafts. Thus, those antigens might be analogous to minor H antigens that have been shown to elicit both skin graft rejection and to induce cytotoxie effeetor T cell activity (32) . However, it is also possible that P815 cells express the same antigen that is detected on the sIg + cells. In this case, the target antigen would most likely be a differentiation antigen with coordinate expression on sIg + cells and P815 cells.
There However, these effector cells did not cause direct lysis of target cells in a 4-h chromium release assay. Further, unlike the specificity of the CTL described in this report, these cells were specific for the epitope which the MOPC 315 cells bind (trinitrophenol) rather than the Ig itself.
Although CTL could play a role in preventing B cell tumors, they may not be relevant in regulating myeloma cell growth because the level of surface Ig on these cells is relatively small (22). On the other hand, tumor cells such as BCL1 may be more amenable to regulation by CTL because these cells generally have a high density of sIg (2) , which could be recognized as a tumor-specific antigen.
It is not known whether the ability of C.B-20 mice to resist BCL1 is due to the activity of CTL. We previously reported (3) that the tumor rejection antigen maps to the V region rather than the C region of the Ig gene complex because BAB-14 mice were tumor susceptible. However, recent data (R. Ciavarra and J. Forman, unpublished data) suggest that for tumor rejection to occur, mice need to recognize two determinants, one in the V region and the other in the C region. A similar conclusion has been drawn in the anti-Qa-1 CTL system (37) . If this interpretation is correct, then the anti-allotype CTL described here could be relevant anti-tumor effector cells. 2 Summary C.B-20 mice were immunized with splenocytes or B leukemia cells (BCL1) from Ig H chain allotype congenic strains. Spleen cells from these immunized mice were rechallenged in vitro to generate H-2-restricted cytotoxic T cells that were specific for target antigens controlled by genes linked to the Ig H chain locus.
The anti-Ig H cytotoxic T cells detected an antigen(s) expressed only on surface Ig ~-cells. Thus, T cell lymphoblasts, eight BALB/c myeloma cell lines, and a T cell lymphoma were not lysed by the effector cells. In contrast, B cell lymphoblasts and the surface Ig + BCL1 cells were sensitive to lysis. A surface Ig-hybridoma (which secretes the IgM from the BCL1 cells) generated by fusing BCL1 cells to X63 myeloma cells was not killed by the effector cells.
These data indicate that cytotoxic T cells specific for antigenic determinants on either surface IgM or IgD or on a molecule that is coordinately expressed on IgM + or IgD + cells can be generated and that such cells might play a role in regulating the growth of normal B cells or surface Ig ÷ tumor cells in vivo.
